Skip to main content
OpenTrials
Completed

NCT Number: NCT02187302

CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)

This study to evaluate treatment in patients with metastatic renal cell carcinoma (RCC) which has progressed through 2 to 3 prior lines of therapy, with the investigational drug CRLX101 in combination with bevacizumab compared to treatment with a standard of care therapy. The study will compare which treatment resulted in longer time before progression of the RCC. Patients will be treated and followed for progression of their disease on average for up to 6 months.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Metastatic Renal Cell Carcinoma Adenocarcinoma Carcinoma Carcinoma, Renal Cell Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Kidney Diseases Kidney Neoplasms Male Urogenital Diseases Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Glandular and Epithelial Urogenital Diseases Urogenital Neoplasms Urologic Diseases Urologic Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

National Cancer Center, Goyang-si Gyeonggi-do, South Korea

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Must have histologically confirmed renal cell carcinoma of any pathologic subtype.
  • Must have unresectable metastatic disease, and have tumor(s) present that is (are) evaluable by the RECIST, v1.1; may have spinal-associated metastases but must have concluded dexamethasone therapy and be evaluated by the Investigator to have stable CNS disease.
  • Must have received 2 or 3 prior lines of conventional molecularly targeted therapy
  • Must have full recovery from any toxicities from prior therapy CTCAE Grade 1 or less with the exception of Grade 2 alopecia) prior to randomization.
  • ECOG performance status 0 or 1.
  • Age 18 years and older.
  • Life expectancy of at least 3 months.
  • Must have normal organ and marrow function reported within 14 days prior to randomization
  • Ability to understand and willingness to sign a written informed consent document.
  • Able to comply with study visit schedule and assessments.

Exclusion criteria

  • Any conventional molecularly targeted therapy within 2 weeks or, chemotherapy or radiotherapy within 2 weeks (local) or 4 weeks (systemic) prior to entering the study.
  • Failure to recover to grade 1 or less all prior adverse events.
  • Any major surgery within 4 weeks of study randomization.
  • Any prior treatment with topoisomerase I therapy.
  • Prior treatment with any drugs or therapies that will be administered during the course of this trial including CRLX101, any topoisomerase 1 inhibitor, bevacizumab or the conventional molecularly targeted agent intended for use as standard of care treatment.
  • Patients receiving any other current investigational therapeutic agent.
  • Other active malignancies
  • Patients with brain metastasis treated or untreated, or other CNS disease
  • Any clinically significant cardiac disease defined as NYHA class III or IV.
  • Uncontrolled hypertension
  • Uncontrolled concurrent illness
  • History of non-healing wounds or ulcers.
  • Pregnancy, or inadequate contraception for men or women of childbearing age, or lactating / breast-feeding
  • Patients with known HIV or with solid organ transplant

Treatment and study plan

CRLX101

Drug

Other names: NLG207

Bevacizumab

Drug

Other names: Avastin

Standard of Care (Investigator Choice)

Drug

Other names: sorafenib (Nexavar), sunitinib (Sutent), axitinib (Inlyta), pazopanib (Votrient), bevacizumab (Avastin),, everolimus (Afinitor), Other

Primary outcomes

  1. Progression Free Survival (PFS)

    Time frame: at least 6 months

    To assess progression free survival (PFS) in patients with clear cell metastatic renal cell carcinoma (RCC) treated with CRLX101 in combination with bevacizumab (CRLX101+bevacizumab) vs. standard of care (SOC) per investigator's choice, as assessed by blinded independent radiological review (IRR) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1

Secondary outcomes

  1. Overall Safety and tolerability (AEs, SAEs, Clinical Laboratory Parameters, Vital Signs, Concomitant Medications)

    Time frame: at least 30 days post last dose of study drug

    AEs will be coded using MedDRA and graded according to CTCAE (v 4.03). The number and percentage of patients with any treatment-emergent AE (TEAE) will be summarized for each treatment group. The number of patients with TEAEs assessed by the Investigator as at least possibly related to treatment will be tabulated. The number of patients with any CTCAE grade ≥ 3 treatment-emergent AE will be tabulated. Serious AEs (SAEs) will also be tabulated.

    For Clinical Laboratory Parameters - Shift tables that present changes from baseline to worst on-study values relative to CTCAE grading will be produced.

    For Vital Signs - By-patient data listings of vital sign measurements will be presented.

    For Concomitant Medications - The use of concomitant medications will be included in by-patient data listings. A summary table of concomitant medications by WHO drug class will also be provided.

  2. Overall survival

    Time frame: on average 12 months after discontinuation of study treatment

    To compare time to death between treatment groups of CRLX101 in combination with bevacizumab compared to SOC.

  3. Objective response rate

    Time frame: at least 6 months

    Evaluate response rates comparing the investigational treatment of CRLX101 in combination with bevacizumab compared to SOC as assessed by blinded IRR as well as by the Investigator

  4. Duration of Response

    Time frame: at least 6 months

    Evaluate time to response comparing the investigational treatment of CRLX101 in combination with bevacizumab compared to SOC as assessed by blinded IRR as well as by the Investigator

  5. PFS

    Time frame: at least 6 months

    To assess PFS in patients with clear cell metastatic RCC treated with CRLX101+bevacizumab vs. SOC per investigator's choice, as assessed at the site level by the Investigator according to RECIST version 1.1

  6. PFS

    Time frame: at least 6 months

    To assess PFS (as assessed at the site level by the Investigator and separately by blinded IRR) in clear cell RCC patients treated with CRLX101+bevacizumab compared to bevacizumab treatment alone

Sponsors and collaborators

Lead sponsor

NewLink Genetics Corporation

Industry

Registry information

Official study title

A Randomized, Phase 2 Study to Assess the Safety and Efficacy of CRLX101 in Combination With Bevacizumab in Patients With Metastatic Renal Cell Carcinoma (RCC) Versus Standard of Care (SOC) (Investigator's Choice)

Important dates

Study start
2014
Primary completion
2016
Study completion
2017
First posted
Jul 11, 2014
Registry last updated
May 28, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.